Innate immune reprogramming to overcome therapy resistance in high-risk colorectal cancer
Dauer: 36 Monate, Fördersumme: € 800.000
Ultra-high-risk pediatric cancer - combinatorial drivers and therapeutic targets for precision medicine
Dauer: 60 Monate, Fördersumme: € 799.350